About this trial
Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies
Eligibility criteria
Qualifiers
Patients with H. pylori infection;
Aged 18-65 years.
Disqualifiers
Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;
Conditions unsuitable for performance of gastroscopy, such as coagulopathy, impaired renal function;
Pregnancy or breastfeeding;
Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.
Trial design
Treatments tested in this trial
- biopsy
- H. pylori eradication
Treatment groups
Locations
1Sponsors and collaborators
Shandong University
Lead sponsor